Government promises to 'reform' Scottish pharmacies by end of 2026

Scottish community pharmacies are set to offer Pharmacy First consultations for a “wider range of health conditions” as part of primary care reforms, C+D has learned.  

The Scottish government will “continue to enhance [its] Pharmacy First programme"

The Scottish government will “reform primary care” by the end of 2026, Member of Scottish Parliament (MSP) John Swinney announced earlier this month (September 4).

While presenting the 2024 programme for government to Scottish parliament, the Scottish National Party (SNP) MSP for Perthshire North said that government must “ensure that our NHS has the resources that it needs, both for today and for years to come”. 

Read more: CPS primes Scottish pharmacies for disappointing funding deal

“We will reform primary care, increasing capacity and access to general practice, community pharmacy, dental and community eyecare services by the end of 2026,” Swinney added.

The Scottish government told C+D that it will “continue to enhance [its] Pharmacy First programme so that a wider range of health conditions are covered”.

Read more: Scotland’s model for pharmacy offers lessons for England’s future

“This will alleviate pressures on the GPs and A&E services and further transfer the care of common clinical conditions to community pharmacy for everyday self-limiting conditions,” it added.

“We will also consider how this aligns with the wider educational reforms that will see all newly registered pharmacists prescriber-ready from 2026,” it said.

Funding flubs?

But in July, Community Pharmacy Scotland (CPS) warned the sector of “stretched” government finances as contract negotiations continued.

At the time, Scotland’s community pharmacy negotiator said it was “prepared to walk away and illustrate the consequences of not being able to reach an agreement”.

It acknowledged that the ongoing contract delays are “not helpful” for contractors facing rising costs and needing “certainty to support investment in their businesses”.

Read more: ‘No role for pharmacists’ in UK’s first safe drug consumption room

Meanwhile last month, Glasgow City Health and Social Partnership (HSPC) announced that the city would launch the first UK space where “people can consume drugs, obtained elsewhere, in the presence of trained health and social care professionals”.

But C+D exclusively revealed that “there is no role identified for pharmacists in the safe drug consumption facility”.

Sign in or register for free

Kate Bowie

Read more by Kate Bowie

Kate Bowie joined C+D as a digital reporter in August 2023 after graduating from a master’s in journalism at City, University of London. She began covering the primary care beat at the end of 2022, when she carried out several health investigations focused on staffing issues, NHS funding and health inequalities.

Latest from News

Kinnock: Collective action is ‘premature, unnecessary and detrimental’

 
• By 
 • comment

The pharmacy minister has urged the NPA to “reconsider” its call for member pharmacies to take collective action from next week, arguing that it will be “detrimental to patients”.

RPS to become Royal College of Pharmacy after 31% voter turnout

 
• By 
 • comment

Seven in ten Royal Pharmaceutical Society (RPS) members who took part in the ballot have voted in favour of controversial plans for the body to become a royal college and register as a charity.

New evidence Brexit caused UK medicines shortages

 
• By 
 • comment

A health and social care think tank has revealed that the “elevated and troubling level” of medicine shortages in the UK can be blamed on Brexit.

More from Clinical

Al-Hassan: Pharmacy prescribing service ‘two or three years’ away

 
• By 
 • comment

MP and pharmacist Sadik Al-Hassan has said the promised community pharmacy prescribing service is “deliverable” but not ready yet.

Pharmacies to boost naloxone stock amid ‘sudden’ overdose spike

 
• By 
 • comment

Pharmacies in Scotland have been asked to ensure they have the “appropriate stock” of naloxone – a medicine used to reverse the effects of an opiate overdose – following an “increase in sudden collapse” due to overdoses.